BRI3

Across TCGA pan-cancer cohorts, BRI3 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of BRI3’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where BRI3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types BRI3 is over-expressed in tumor, although a few such as LSCC and LUAD show the opposite, repressed pattern.

COAD, LSCC, and LUAD are the cancer types where BRI3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in BRI3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Male	II,III,IV	+0.381	<.001	11	view →
LSCC	Female	All	−0.523	<.001	8	view →
LUAD	Male	All	−0.320	<.001	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

BRI3–COAD

Open the COAD breakdown →